Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2013

01.11.2013 | Basic Science

Inhibitory effects of topical cyclosporine A 0.05 % on immune-mediated corneal neovascularization in rabbits

verfasst von: Yasin Yücel Bucak, Mesut Erdurmus, Elçin Hakan Terzi, Aysel Kükner, Serdal Çelebi

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

We aimed to study the inhibitory effects of topical cyclosporine A (CsA) 0.05 % on immune-mediated corneal neovascularization, and to compare its efficacy with those of dexamethasone 0.1 % and bevacizumab 0.5 %.

Methods

Immune-mediated corneal neovascularization was created in 36 right eyes of 36 rabbits. The rabbits were then randomized into four groups. Group I received CsA 0.05 %, Group II received dexamethasone 0.1 %, Group III received bevacizumab 0.5 %, and Group IV received isotonic saline twice a day for 14 days. The corneal surface covered with neovascular vessels was measured on the photographs. The rabbits were then sacrificed and the corneas excised. Paraffin-embedded sections were stained with hematoxylin-eosin and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling assay.

Results

The means of percent area of corneal neovascularization in Group I, II, III, and IV were 24.4 %, 5.9 %, 37.1 %, and 44.1 %, respectively. The inhibitory effect of CsA 0.05 % was found to be better than the effect found in the bevacizumab 0.5 % and control groups (p = 0.03 and p = 0.02, respectively). CsA 0.05 % was found to have significantly lesser inhibitory effects on corneal neovascularization than dexamethasone 0.1 % (p < 0.001). Apoptotic cell density was higher in Group III and Group IV than in Group I and Group II. There was no difference between Group I and Group II in terms of apoptotic cell density (p = 0.7).

Conclusions

Topical CsA 0.05 % was shown to have an inhibitory effect on immune-mediated corneal neovascularization in rabbits.
Literatur
1.
Zurück zum Zitat Prabhasawat P, Tesavibul N, Mahawong W (2012) A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 31:1386–9133PubMedCrossRef Prabhasawat P, Tesavibul N, Mahawong W (2012) A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 31:1386–9133PubMedCrossRef
2.
Zurück zum Zitat Schechter BA, Katz RS, Friedman LS (2009) Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 26:651–659PubMedCrossRef Schechter BA, Katz RS, Friedman LS (2009) Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 26:651–659PubMedCrossRef
3.
Zurück zum Zitat Salib GM, McDonald MB, Smolek M (2006) Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 32:772–728PubMedCrossRef Salib GM, McDonald MB, Smolek M (2006) Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 32:772–728PubMedCrossRef
4.
Zurück zum Zitat Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S (1998) A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 105:1715–1720PubMedCrossRef Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S (1998) A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 105:1715–1720PubMedCrossRef
5.
Zurück zum Zitat Poon A, Constantinou M, Lamoureux E, Taylor HR (2008) Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Exp Ophthalmol 36:415–421 Poon A, Constantinou M, Lamoureux E, Taylor HR (2008) Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Exp Ophthalmol 36:415–421
6.
Zurück zum Zitat Rao SN, Rao RD (2006) Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. Cornea 25:674–678PubMedCrossRef Rao SN, Rao RD (2006) Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. Cornea 25:674–678PubMedCrossRef
7.
Zurück zum Zitat Okumus S, Coskun E, Tatar MG, Kaydu E, Yayuspayi R, Comez A, Erbagci I, Gurler B (2012) Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol 12:42PubMedCrossRef Okumus S, Coskun E, Tatar MG, Kaydu E, Yayuspayi R, Comez A, Erbagci I, Gurler B (2012) Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol 12:42PubMedCrossRef
8.
Zurück zum Zitat Williams KA, Coster DJ (2007) The immunobiology of corneal transplantation. Transplantation 84:806–813PubMedCrossRef Williams KA, Coster DJ (2007) The immunobiology of corneal transplantation. Transplantation 84:806–813PubMedCrossRef
9.
Zurück zum Zitat Liu Y, Jiang J, Xiao H, Wang X, Li Y, Gong Y, Wang D, Huang Y (2012) Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice. Mol Vis 18:624–633PubMed Liu Y, Jiang J, Xiao H, Wang X, Li Y, Gong Y, Wang D, Huang Y (2012) Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice. Mol Vis 18:624–633PubMed
10.
Zurück zum Zitat Hernández GL, Volpert OV, Iñiguez MA, Lorenzo E, Martínez-Martínez S, Grau R, Fresno M, Redondo JM (2001) Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 193:607–620PubMedCrossRef Hernández GL, Volpert OV, Iñiguez MA, Lorenzo E, Martínez-Martínez S, Grau R, Fresno M, Redondo JM (2001) Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 193:607–620PubMedCrossRef
11.
Zurück zum Zitat Benelli U, Ross JR, Nardi M, Klintworth GK (1997) Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 38:274–282PubMed Benelli U, Ross JR, Nardi M, Klintworth GK (1997) Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 38:274–282PubMed
12.
Zurück zum Zitat Saita N, Fujiwara N, Yano I, Soejima K, Kobayashi K (2000) Trehalose 6,6′-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats. Infect Immun 68:5991–5997PubMedCrossRef Saita N, Fujiwara N, Yano I, Soejima K, Kobayashi K (2000) Trehalose 6,6′-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats. Infect Immun 68:5991–5997PubMedCrossRef
13.
Zurück zum Zitat Peebo BB, Fagerholm P, Traneus-Röckert C, Lagali N (2011) Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model. Angiogenesis 14:393–405PubMedCrossRef Peebo BB, Fagerholm P, Traneus-Röckert C, Lagali N (2011) Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model. Angiogenesis 14:393–405PubMedCrossRef
14.
Zurück zum Zitat Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514–2522PubMed Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514–2522PubMed
15.
Zurück zum Zitat Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249PubMedCrossRef Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249PubMedCrossRef
16.
Zurück zum Zitat Epstein RJ, Stulting RD, Hendricks RL, Harris DM (1987) Corneal neovascularization: pathogenesis and inhibition. Cornea 6:250–257PubMedCrossRef Epstein RJ, Stulting RD, Hendricks RL, Harris DM (1987) Corneal neovascularization: pathogenesis and inhibition. Cornea 6:250–257PubMedCrossRef
17.
Zurück zum Zitat Lee P, Wang CC, Adamis AP (1998) Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 43:245–269PubMedCrossRef Lee P, Wang CC, Adamis AP (1998) Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 43:245–269PubMedCrossRef
18.
Zurück zum Zitat Erdurmus M, Yagci R, Yilmaz B, Hepsen IF, Turkmen C, Aydin B, Karadag R (2007) Inhibitory effects of topical thymoquinone on corneal neovascularization. Cornea 26:715–719PubMedCrossRef Erdurmus M, Yagci R, Yilmaz B, Hepsen IF, Turkmen C, Aydin B, Karadag R (2007) Inhibitory effects of topical thymoquinone on corneal neovascularization. Cornea 26:715–719PubMedCrossRef
19.
Zurück zum Zitat Jones IS, Meyer K (1950) Inhibition of vascularization of the rabbit cornea by local application of cotisone. Proc Soc Exp Biol Med 74:102–104PubMedCrossRef Jones IS, Meyer K (1950) Inhibition of vascularization of the rabbit cornea by local application of cotisone. Proc Soc Exp Biol Med 74:102–104PubMedCrossRef
20.
Zurück zum Zitat Baratz KH, Hattenhauer MG (1999) Indiscriminate use of corticosteroid-containing eyedrops. Mayo Clin Proc 74:362–366PubMedCrossRef Baratz KH, Hattenhauer MG (1999) Indiscriminate use of corticosteroid-containing eyedrops. Mayo Clin Proc 74:362–366PubMedCrossRef
21.
Zurück zum Zitat Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577–1579PubMedCrossRef Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577–1579PubMedCrossRef
22.
Zurück zum Zitat Bock F, König Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281–284PubMedCrossRef Bock F, König Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281–284PubMedCrossRef
23.
Zurück zum Zitat Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, Tuft SJ (2013) Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol 97:28–32PubMedCrossRef Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, Tuft SJ (2013) Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol 97:28–32PubMedCrossRef
24.
Zurück zum Zitat Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, Pavan-Langston D, Dana R (2009) Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 127:381–389PubMedCrossRef Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, Pavan-Langston D, Dana R (2009) Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 127:381–389PubMedCrossRef
25.
Zurück zum Zitat Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375–1382PubMedCrossRef Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375–1382PubMedCrossRef
26.
Zurück zum Zitat Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J (2003) VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 44:117–123PubMedCrossRef Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J (2003) VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 44:117–123PubMedCrossRef
27.
Zurück zum Zitat Bock F, Konig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye [in German]. Ophthalmologe 104:336–344PubMedCrossRef Bock F, Konig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye [in German]. Ophthalmologe 104:336–344PubMedCrossRef
28.
Zurück zum Zitat Küchle M, Cursiefen C, Nguyen NX, Langenbucher A, Seitz B, Wenkel H, Martus P, Naumann GO (2002) Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol 240:580–584PubMedCrossRef Küchle M, Cursiefen C, Nguyen NX, Langenbucher A, Seitz B, Wenkel H, Martus P, Naumann GO (2002) Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol 240:580–584PubMedCrossRef
29.
Zurück zum Zitat Maier P, Bohringer D, Reinhard T (2007) Clear graft survival and immune reactions following emergency keratoplasty. Graefes Arch Clin Exp Ophthalmol 245:351–359PubMedCrossRef Maier P, Bohringer D, Reinhard T (2007) Clear graft survival and immune reactions following emergency keratoplasty. Graefes Arch Clin Exp Ophthalmol 245:351–359PubMedCrossRef
30.
Zurück zum Zitat Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A (1994) Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative corneal transplantation studies research group. Ophthalmology 101:1536–1547PubMed Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A (1994) Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative corneal transplantation studies research group. Ophthalmology 101:1536–1547PubMed
31.
Zurück zum Zitat Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K (2011) Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol 152:33–39.e1PubMedCrossRef Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K (2011) Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol 152:33–39.e1PubMedCrossRef
32.
Zurück zum Zitat Gupta D, Illingworth C (2011) Treatments for corneal neovascularization: a review. Cornea 30:927–938PubMedCrossRef Gupta D, Illingworth C (2011) Treatments for corneal neovascularization: a review. Cornea 30:927–938PubMedCrossRef
33.
Zurück zum Zitat Lipman RM, Epstein RJ, Hendricks RL (1992) Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 110:405–407PubMedCrossRef Lipman RM, Epstein RJ, Hendricks RL (1992) Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 110:405–407PubMedCrossRef
34.
Zurück zum Zitat Cho ML, Cho CS, Min SY, Kim SH, Lee SS, Kim WU, Min DJ, Min JK, Youn J, Hwang SY, Park SH, Kim HY (2002) Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 46:1202–1209PubMedCrossRef Cho ML, Cho CS, Min SY, Kim SH, Lee SS, Kim WU, Min DJ, Min JK, Youn J, Hwang SY, Park SH, Kim HY (2002) Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 46:1202–1209PubMedCrossRef
35.
Zurück zum Zitat Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R (2011) Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 52:8718–8723PubMedCrossRef Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R (2011) Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 52:8718–8723PubMedCrossRef
Metadaten
Titel
Inhibitory effects of topical cyclosporine A 0.05 % on immune-mediated corneal neovascularization in rabbits
verfasst von
Yasin Yücel Bucak
Mesut Erdurmus
Elçin Hakan Terzi
Aysel Kükner
Serdal Çelebi
Publikationsdatum
01.11.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2013
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-013-2467-4

Weitere Artikel der Ausgabe 11/2013

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2013 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.